Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

2.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.2K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

7.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

769
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
769

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interlaboratory exercise on the use of immunofluorescence microscopy on the blood smear for recognizing inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelets in Health and Disease.

Journal of thrombosis and haemostasis : JTH·2026
Same author

When increased bone marrow blasts may not mean malignancy.

Blood·2025
Same author

Characterization of a novel <i>FLI1</i> mutation in a family with thrombocytopenia and other congenital malformations.

Haematologica·2025
Same author

Transcription factor RUNX1 regulates coagulation factor XIII-A (<i>F13A1</i>): decreased platelet-megakaryocyte <i>F13A1</i> expression and clot contraction in <i>RUNX1</i> haplodeficiency.

Research and practice in thrombosis and haemostasis·2025
Same author

Microbiological diversity among patients with Lemierre syndrome and clinical implications: an individual patient-level analysis.

Infection·2025
Same author

Transcription Factor RUNX1 Regulates Coagulation Factor XIII-A ( <i>F13A1</i> ): Decreased Platelet-Megakaryocyte <i>F13A1</i> Expression and Clot Contraction in <i>RUNX1</i> Haplodeficiency.

medRxiv : the preprint server for health sciences·2025
Same journal

From monoclonal to polyfunctional immunotherapy: Reprogramming CAR-T-cell therapy with oncolytic viruses in B-cell malignancies.

HemaSphere·2026
Same journal

Inflammatory signatures in the spectrum of myeloid diseases.

HemaSphere·2026
Same journal

Should flow cytometry be required for CMML diagnosis? Position of the ELN iMDS Flow Working Group.

HemaSphere·2026
Same journal

Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.

HemaSphere·2026
Same journal

Multiple myeloma: A tale of deregulated transcription factors.

HemaSphere·2026
Same journal

Transitioning CAR-T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta-cel in Germany.

HemaSphere·2026
See all related articles

Related Experiment Video

Updated: Oct 21, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K

The EHA Research Roadmap: Platelet Disorders

Carlo Balduini1, Kathleen Freson2, Andreas Greinacher3

  • 1Ferrata-Storti Foundation, Pavia, Italy.

Hemasphere
|September 3, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

645
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.0K

Related Experiment Videos

Last Updated: Oct 21, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

645
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.0K